Last reviewed · How we verify
IRX-101
IRX-101 is an intravenous immunoglobulin (IVIG) formulation designed to modulate immune responses and reduce inflammation.
IRX-101 is an intravenous immunoglobulin (IVIG) formulation designed to modulate immune responses and reduce inflammation. Used for Chronic inflammatory demyelinating polyneuropathy (CIDP).
At a glance
| Generic name | IRX-101 |
|---|---|
| Also known as | Test Arm 1 |
| Sponsor | iRenix Medical, Inc. |
| Drug class | Intravenous immunoglobulin (IVIG) |
| Target | Fc receptors, complement system |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
IRX-101 is a polyclonal immunoglobulin G (IgG) preparation derived from pooled human plasma that works through multiple immunomodulatory mechanisms, including Fc receptor engagement, complement modulation, and anti-inflammatory cytokine induction. It is being developed to treat conditions characterized by dysregulated immune responses and excessive inflammation.
Approved indications
- Chronic inflammatory demyelinating polyneuropathy (CIDP)
Common side effects
- Headache
- Fever
- Chills
- Infusion-related reactions
- Thrombosis
Key clinical trials
- Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections (PHASE3)
- SteRilizing Eye SoLution to ImprovE Patient ComFort (RELIEF) (PHASE2)
- EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |